Eli Lilly and Company $LLY Shares Sold by GLOBALT Investments LLC GA

Key Points

• GLOBALT Investments LLC reduced its holdings in Eli Lilly and Company by 15.5%, selling 2,364 shares in the second quarter, now holding shares valued at $10,076,000.
• Eli Lilly reported $6.31 EPS for the last quarter, beating forecasts by $0.72, and achieving a revenue increase of 37.6% year-over-year.
• Wall Street analysts maintain a mostly positive outlook, with an average price target of $938.61, reflecting multiple upgrades and a mix of "buy" and "hold" ratings.

GLOBALT Investments LLC GA lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 15.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,925 shares of the company's stock after selling 2,364 shares during the period. GLOBALT Investments LLC GA's holdings in Eli Lilly and Company were worth $10,076,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. LJI Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 10.6% in the 2nd quarter. LJI Wealth Management LLC now owns 7,822 shares of the company's stock worth $6,098,000 after acquiring an additional 748 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of Eli Lilly and Company by 0.6% during the second quarter. Asset Management One Co. Ltd. now owns 366,233 shares of the company's stock valued at $285,490,000 after acquiring an additional 2,082 shares during the period. Lazard Freres Gestion S.A.S. raised its holdings in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock worth $60,253,000 after purchasing an additional 41,222 shares in the last quarter. R Squared Ltd acquired a new stake in Eli Lilly and Company in the second quarter worth approximately $505,000. Finally, AlTi Global Inc. boosted its stake in Eli Lilly and Company by 29.0% during the 2nd quarter. AlTi Global Inc. now owns 1,712 shares of the company's stock valued at $1,342,000 after purchasing an additional 385 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 1.1%

Shares of LLY opened at $820.97 on Friday. The business's 50-day moving average price is $765.52 and its 200 day moving average price is $767.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $777.01 billion, a P/E ratio of 53.66, a P/E/G ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm earned $3.92 earnings per share. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Tuesday, October 14th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Finally, The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a report on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $938.61.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.